Jo Wick

Jo Wick

Auto-generated profile, based on publicly available information

Jo Wick

University of Kansas Medical Center, Kansas City, KS, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
NNNicole L. Nollen
Nicole L. Nollen
JWJo Wick
Jo Wick
DHDorothy Hughes
Dorothy Hughes
DWDanny R. Welch
Danny R. Welch
ECElizabeth Calhoun
Elizabeth Calhoun
How the socioeconomic factors intersect for a particular patient can determine their susceptibility to financial toxicity, what costs they will encounter during treatment, the type and quality of their care, and the potential work impairments they face. The primary goal of this study was to evaluate financial factors leading to worsening health outcomes by the cancer subtype. A logistic model predicting worsening health outcomes while assessing the most influential economic factors was constructed by the University of Michigan Health and Retirement Study. A forward stepwise regression procedure was implemented to identify the social risk factors that impact health status. Stepwise regression was done on data subsets based on the cancer types of lung, breast, prostate, and colon cancer to determine whether significant predictors of worsening health status were different or the same across cancer types. Independent covariate analysis was also conducted to cross-validate our model. On the basis of the model fit statistics, the two-factor model has the best fit, that is, the lowest AIC among potential models of 3270.56, percent concordance of 64.7, and a C-statistics of 0.65. The two-factor model used work impairment and out-of-pocket costs, significantly contributing to worsening health outcomes. Covariate analysis demonstrated that younger patients with cancer experienced more financial burdens leading to worsening health outcomes than elderly patients aged 65 years and above. Work impairment and high out-of-pocket costs were significantly associated with worsening health outcomes among cancer patients. Matching the participants who need the most financial help with appropriate resources is essential to mitigate the financial burden. Significance: Among patients with cancer, work impairment and out-of-pocket are the two primary factors contributing to adverse health outcomes. Women, African American or other races, the Hispanic population, and younger individuals have encountered higher work impairment and out-of-pocket costs due to cancer than their counterparts.

1 September 2021 in Preventive Medicine Reports
Verified
Journal Article
Open access
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
MPMichele Park
Michele Park
JTJeffrey Thompson
Jeffrey Thompson
AAAlexander M. Alsup
Alexander M. Alsup
RKRon Krebill
Ron Krebill
TGTami Gurley-Calvez
Tami Gurley-Calvez
• An abnormal mammogram was positively associated with family history and hormonal contraceptives. • It was found that older patients, those who were married, are more likely to get screened. • Those who had their first pregnancy at an older age are at higher risk of having an abnormal mammogram.

19 May 2023 in Communications in Statistics: Case Studies, Data Analysis and Applications
Verified
Journal Article
Closed access
GGGuangyi Gao
Guangyi Gao
JWJo A. Wick
Jo A. Wick
ABAlexandra R. Brown
Alexandra R. Brown
RBRichard J. Barohn
Richard J. Barohn
BGByron Gajewski
Byron Gajewski
The PAIN-CONTRoLS trial compared four medications in treating Cryptogenic sensory polyneuropathy. The primary outcome was a utility function that combined two outcomes, patients' pain score reduction and patients' quit rate. However, additional analysis of the individual outcomes could also be leveraged to inform selecting an optimal medication for future patients. We demonstrate how joint modeling of longitudinal and time-to-event data from PAIN-CONTRoLS can be used to predict the effects of medication in a patient-specific manner and helps to make patient-focused decisions. A joint model was used to evaluate the two outcomes while accounting for the association between the longitudinal process and the time-to-event processes. Results suggested no significant association between the patients' pain scores and time to the medication quit in the PAIN-CONTRoLS study, but the joint model still provided robust estimates and a better model fit. Using the model estimates, given patients' baseline characteristics, a drug profile on both the pain reduction and medication time could be obtained for each drug, providing information on how likely they would quit and how much pain reduction they should expect. Our analysis suggested that drugs viable for one patient may not be beneficial for others.

19 February 2024 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
XSXiaosong Shi
Xiaosong Shi
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
JWJo A. Wick
Jo A. Wick
DSDavid Streeter
David Streeter
JTJeffrey A. Thompson
Jeffrey A. Thompson
BGByron Gajewski
Byron Gajewski
Slow patient accrual in cancer clinical trials is always a concern. In 2021, the University of Kansas Comprehensive Cancer Center (KUCC), an NCI-designated comprehensive cancer center, implemented the Curated Cancer Clinical Outcomes Database (C3OD) to perform trial feasibility analyses using real-time electronic medical record data. In this study, we proposed a Bayesian hierarchical model to evaluate annual cancer clinical trial accrual performance. The Bayesian hierarchical model uses Poisson models to describe the accrual performance of individual cancer clinical trials and a hierarchical component to describe the variation in performance across studies. Additionally, this model evaluates the impacts of the C3OD and the COVID-19 pandemic using posterior probabilities across evaluation years. The performance metric is the ratio of the observed accrual rate to the target accrual rate. Posterior medians of the annual accrual performance at the KUCC from 2018 to 2023 are 0.233, 0.246, 0.197, 0.150, 0.254, and 0.340. The COVID-19 pandemic partly explains the drop in performance in 2020 and 2021. The posterior probability that annual accrual performance is better with C3OD in 2023 than pre-pandemic (2019) is 0.935. This study comprehensively evaluates the annual performance of clinical trial accrual at the KUCC, revealing a negative impact of COVID-19 and an ongoing positive impact of C3OD implementation. Two sensitivity analyses further validate the robustness of our model. Evaluating annual accrual performance across clinical trials is essential for a cancer center. The performance evaluation tools described in this paper are highly recommended for monitoring clinical trial accrual.

17 June 2024 in Statistics in Medicine
Verified
Journal Article
Closed access
XSXiaosong Shi
Xiaosong Shi
JWJo A. Wick
Jo A. Wick
RMRenee' L. Martin
Renee' L. Martin
JBJonathan Beall
Jonathan Beall
RSRobert Silbergleit
Robert Silbergleit
BGByron Gajewski
Byron Gajewski

5 July 2023
Verified
Other
Open access
DMDinesh Pal Mudaranthakam
Dinesh Pal Mudaranthakam
NNNicole Nollen
Nicole Nollen
JWJo Wick
Jo Wick
DHDorothy Hughes
Dorothy Hughes
DWDanny Welch
Danny Welch
ECElizabeth Calhoun
Elizabeth Calhoun
Logistic regression of full model of main effects